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Abstract
Background
Biomarkers are a key component of precision medicine. However, full clinical integration of
biomarkers has been met with challenges, partly attributed to analytical difficulties. It has
been shown that biomarker reproducibility is susceptible to data preprocessing approaches.
Here, we systematically evaluated machine-learning ensembles of preprocessing methods
as a general strategy to improve biomarker performance for prediction of survival from early
breast cancer.
Results
We risk stratified breast cancer patients into either low-risk or high-risk groups based on four
published hypoxia signatures (Buffa, Winter, Hu, and Sorensen), using 24 different prepro-
cessing approaches for microarray normalization. The 24 binary risk profiles determined for
each hypoxia signature were combined using a random forest to evaluate the efficacy of a
preprocessing ensemble classifier. We demonstrate that the best way of merging prepro-
cessing methods varies from signature to signature, and that there is likely no ‘best’ prepro-
cessing pipeline that is universal across datasets, highlighting the need to evaluate
ensembles of preprocessing algorithms. Further, we developed novel signatures for each
preprocessing method and the risk classifications from each were incorporated in a meta-
random forest model. Interestingly, the classification of these biomarkers and its ensemble
show striking consistency, demonstrating that similar intrinsic biological information are
being faithfully represented. As such, these classification patterns further confirm that there
is a subset of patients whose prognosis is consistently challenging to predict.
Conclusions
Performance of different prognostic signatures varies with pre-processing method. A simple
classifier by unanimous voting of classifications is a reliable way of improving on single
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Introduction
Cancer is fundamentally a disease driven by genetic alterations, with the stepwise accumula-
tion of mutational hits in oncogenes and tumor suppressors [1]. However, cancer is not one
disease but many, with significant variability between tumor subtypes and within individual
tumours in both the rate of mutation and the specific genes that are mutated [2]. Conse-
quently, the molecular landscape of tumours can vary wildly, leading to differences in progres-
sion and overall prognosis. These differences are described as genetic heterogeneity, while
intra-tumor heterogeneity refers to heterogeneity within a tumor [3–6].
Currently, treatment decisions for individual patients are largely based on tumor subtype,
histology and pathology; clinico-pathological correlation; and tumor size, nodal and metastatic
status (TNM stage), along with a few molecular characteristics. This approach does not
account for the wide spectrum of genetic burden experienced by the individual patients, lead-
ing to divergent responses to therapy that are currently unpredictable. Accordingly, biomark-
ers play a key role in the realization of precision oncology to determine the treatment that
generates optimal response with minimal toxicity [7]. Biomarkers could be used at all stages of
disease management, including prognosis (determining an individual patient’s likely course of
disease-related outcomes such as recurrence and survival), or drug-sensitivity prediction [8,
9]. An ideal biomarker may predict multiple of these end-points simultaneously, and current
research focuses on creating panels of biomarkers for each disease.
To this end, numerous groups have sought to develop transcriptomic biomarkers using
microarray and RNA-sequencing approaches [7]. These efforts have resulted in a wide spec-
trum of signatures with prognostic potential, with the hope of fulfilling the gap between the
underlying genomic heterogeneity and clinical oncology. However, few of these signatures
have been successfully translated into routine clinical practice [10]. There are several reasons
for this high failure rate of biomarkers [11]. First, there is little overlap in the genes incorpo-
rated across biomarkers, leading to criticism that variability in the experimental and computa-
tional techniques introduce artificial noise [12, 13]. Second, signatures have been derived from
a variety of sources including cell lines, transgenic mouse models, combination of biological
pathways known to be perturbed in tumor subtypes, and profiling of tumor specimens. Third,
small sample size with low statistical power limits the generalizability of the signatures [14].
Fourth, biases often exist between the training and testing populations, yielding a signature
that reflects interdependencies between known clinical variables [15]. Fifth, the lack of guide-
lines on strenuous evaluation of biomarker performance in independent validation datasets
further accentuates false-positive rates and confuses the literature [14]. Finally, lack of stan-
dardized preprocessing methods challenge the consistency of the data obtained, which is often
re-used in secondary studies.
Several groups have demonstrated that biomarker reproducibility is highly sensitive to the
choice of preprocessing algorithm [13, 16, 17]. For example, we demonstrated that applying 24
preprocessing techniques for mRNA abundance normalization and predicting two established
signatures led to only ~33% of patients having consistent predictions in a cohort of 442 non-
small cell lung cancer (NSCLC) patients [18]. Surprisingly, those patients with unanimous pre-
dictions across all preprocessing methods had more robust classifications than those from any
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individual preprocessing algorithm alone. These findings were corroborated when we evalu-
ated pipeline concordance in a cohort of 1,564 early breast cancers using hypoxia signatures.
The ensemble approach of merging multiple preprocessing methods improved the perfor-
mance of hypoxia signatures, outperforming any individual method [19].
Hypoxia is the result of cancer altering cellular metabolism to focus on anaerobic glycolysis
along with the tortuous nature of their blood vessels [19]. Hypoxic regions of the tumor have
been implicated in promoting genomic heterogeneity, genomic instability and subclonal
expansion of a more aggressive tumor cells [20, 21]. The selective pressures experienced by
tumor cells in hypoxic conditions consequentially results in altered gene expression by epige-
netics and transcription factor activation for angiogenesis, and gaining of metastatic features.
Hypoxia is associated with poor prognosis and treatment failure, prompting the development
of several biomarkers to identify such patients [21, 22].
It is unclear why this ensemble-of-preprocessing methods approach works so effectively.
One hypothesis is that each individual preprocessing removes a different aspect of underlying
noise in the microarray dataset, and that the merged ensemble of noise reduction from various
perspectives allows a more accurate estimate of the true biomarker signal. The vast majority of
current implementations involve simple voting, which may significantly underestimate the
advantages of ensembles. Further, unanimous voting classification method leaves a large frac-
tion (36%-80% depending on the signature) of patients unclassified. To try to bring such
approaches to greater clinical utility, we set out to systematically evaluate whether ensembles
of preprocessing methods may improve classification in a greater proportion of patients. We
replaced the simple voting scheme with supervised machine-learning and evaluated a broad
range of signatures.
Methods
Datasets
To systematically evaluate the impact of preprocessing ensemble classifier on risk stratification,
two separate sets primary breast cancer mRNA abundance were gathered. First, eight datasets
profiled on the Affymetrix Human Genome U133A (HG-U133A) microarray platform were
obtained and integrated, comprising a total of 1,564 early breast cancer patients [23–30]. Sec-
ond, two datasets profiled on the Affymetrix Human Genome Plus 2.0 (HG-U133 Plus 2.0)
GeneChip Array were obtained for a total of 579 early breast cancer patients [31, 32]. All sam-
ples incorporated in the analysis were surgical specimens taken prior to any treatment. To ver-
ify the ensemble method can be effective in other data types, a prostate cancer methylation
preprocessing dataset containing 310 samples normalized using 11 different strategies was
used [33].
Preprocessing pipelines
To evaluate the performance of preprocessing ensemble classifiers learnt from various prepro-
cessing pipelines, data from the two microarray platform datasets specified above were prepro-
cessed in 24 different ways. There were three aspects that were considered to yield the unique
24 preprocessing methods: six preprocessing algorithms, two gene annotation methods, and
two dataset handling procedures. The combinations of these that precipitate the 24 preprocess-
ing pipelines were carried out as previously described [19]. Briefly, the six preprocessing algo-
rithms include 4 without log2-transformation [Robust Multi-array Average (RMA) [34],
MicroArray Suite 5.0 (MAS5) [35], Model-base Expression Index (MBEI) [36], GeneChip
Robust Multi-array Average (GCRMA) [37], and 2 log2-transform versions of MAS5 and
MBEI. These algorithms were all available in the R statistical environment (R packages: affy
Ensembles of hypoxia signatures
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v1.36.0, gcrma v2.30.0). S1 Table provides a brief summary of each of these algorithms. The
two dataset handling approaches include either independent or merged preprocessing. The
two ProbeSet annotations used were either default Affymetrix gene-annotation (R packages:
hgu133aprobe v2.10.0, hgu133acdf v2.10.0, hgu133a.db v2.8.0, hgu133plus2probe v2.6.0,
hgu133plus2cdf v2.6.0, hgu133plus2.db v2.8.0) or an alternative Entrez Gene-based updated
annotation (R pack- ages: hgu133ahsentrezgprobe v15.1.0, hgu133ahsentrezgcdf v15.0.0,
hgu133plus2hsentrezgprobe v15.1.0, hgu133- plus2hsentrezgcdf v15.1.0). S2 Table provides a
summary of each of these preprocessing pipelines.
Patient risk classification: Hypoxia signatures
To assess the influence of preprocessing variation on risk stratification of patients, we used
four published hypoxia gene signatures: Buffa metagene [38], Winter metagene [39], Hu signa-
ture [40], and Sorensen gene set [41]. These signatures were chosen as they exhibited the best
performance in predicting patient outcome in our previous work. Briefly, each gene signature
was used to stratify patients into either low-risk or high-risk. Following pre-processing of data
using pipelines, the multi-gene signature score was calculated for each patient using all genes
on the signature’s gene list. First, for each gene of the signature, patients were median dichoto-
mized (0 or 1) based on the signal-intensity of the gene compared to the expression level of
that gene across all patients. Next, the multi-gene signature score for each patient was calcu-
lated as the sum of all gene scores. Finally, the scores were used to median dichotomize
patients into high and low risk groups for each signature.
For preprocessing pipelines with independent dataset preprocessing, stratification was con-
ducted independently. In preprocessing pipelines with merged dataset preprocessing, stratifi-
cation was conducted simultaneously. In summary, for each patient, 24 risk classifications
(high or low risk) was derived from 24 different pre-processing pipelines based on gene signa-
ture expression.
Brief descriptions of the original studies deriving these signatures are provided in S3 Table.
Of note, genes contained in these signatures are genes that were found to be upregulated in
hypoxic tumor environments, resulting in worse prognosis.
Ensemble classifier: Risk classification votes
The primary endpoint was to delineate whether an ensemble of preprocessing pipeline classifi-
ers using hypoxia signatures may improve the prediction of prognosis in early breast cancer
patients beyond that achieved by single pipeline classifiers. Since cause-specific mortality data
is lacking in our study, individual patient survival outcome was defined as either 0 or 1 to rep-
resent dead or alive status at 5-years, respectively (events occurred after 5-years were cen-
sored). Five-year survival was chosen as it is an important survival time-point for breast cancer
survivors due to the increasing causes of death unrelated to breast cancer in subsequent survi-
vorship years. At the end of 5 years, 1193 were censored while 371 cancer-related events
occurred for patients profiled on the HG-U133A platform. For patients profiled on the
HG-U133 Plus 2.0 platform, 352 were censored while 227 events occurred.
The 24 dichotomized risk profiles determined from each hypoxia signature were combined
to develop a preprocessing ensemble classifier using random forest (randomForest package
v4.6.10) to stratify patients within the HG-U133A and HG-U133A Plus 2.0 datasets, respec-
tively, as good or poor prognosis. The HG-U133A and HG-U133A Plus 2.0 datasets were inde-
pendently separated into training and testing sets by a sample size ratio of 1:1. Random
sampling was employed to determine the training and testing set, maintaining a balanced ratio
between mortality and survival events in subsequent datasets. Random forest classifier was
Ensembles of hypoxia signatures
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trained on the training set of HG-U133A and HG-U133A Plus 2.0, respectively, to prognosti-
cate survival. Parameter was set at the upper limit of the total number of events in the training
set to maintain equal sampling from patients who survived and those who experienced an
event at 5 years. Tuning of random forest classifier parameters mtry (values 1, 2, 4, 6, 8, 10, 12,
14, 16, 18, 20, 22, 24) and ntree (values 500, 1000, 2000, 5000) was done using grid. The best
tuning parameters for the final classifier were selected based on the performance measure
accuracy, as specified below.
The test dataset was evaluated using each of the tuned models to produce 0 or 1 to predict
whether each patient died by 5 years. To calculate performance, patients alive at 5 years were
considered to be true negatives (TNs) if the classifier correctly assigned them to good progno-
sis group, whereas they were considered as false negatives (FNs) if they died within 5 years.
Similarly, patients who died within 5 years were considered to be true positives (TPs) if the
classifier correctly assigned them to poor prognosis group, whereas they were considered as
false positives (FPs) if they were alive at 5 years. Subsequently, sensitivity, specificity, and accu-
racy were calculated accordingly. The area under the receiver operator curve (AUC) was calcu-
lated based on the receiver operator characteristic (ROC) analysis using the random forest
classification probability (pROC v1.8). The final tuning parameters selected were those that
yielded the highest accuracy.
Ensemble classifier: Engineered variables
Following random forest classification using only the risk classification votes from different
pipeline variants, classifiers were constructed using summary statistics as additional features.
The engineered summary variables capture the total number of poor prognosis votes based on
the variable aspects of preprocessing pipelines as follows: total number votes overall, total
number of votes for pipelines using separate preprocessing, total number of votes for pipelines
using merged preprocessing, total number of votes for RMA pipelines, total number of votes
for GCRMA pipelines, total number of votes for MBEI pipelines, total number of votes for
MAS5 pipelines, total number of votes for log2 MBEI pipelines, total number of votes for log2
MAS5 pipelines, total number of votes for RMA and MAS5 pipelines, total number of votes
for pipelines using default annotation, and total number of votes for pipelines using alternative
annotation. The derivation of engineered variables is summarized in S4 Table.
Random forest models were built upon the following feature combinations: ensemble of
preprocessing pipeline variants and the engineered variables, ensemble of engineered vari-
ables, and ensemble of only feature variables selected by the Boruta algorithm (Boruta v4.0.0).
Random forest models were tuned based on performance similar to above. For the HG-U133A
dataset, models were constructed by incorporating all patients in the cohort or only the subset
of patients with unanimous agreement across the preprocessing pipelines. For the HG-U133A
Plus 2.0 dataset, given the smaller sample size, models were constructed by incorporating all
patients in the cohort to maintain sufficient statistical power.
Classifier evaluation
The prognostic performance of the tuned classifiers was evaluated on the test set Kaplan-Meier
estimates with the log-rank test and unadjusted Cox proportional hazard ratio model used to
compare between the two groups (survival v2.38.0). In order to assess the performance of ran-
dom forest-based ensemble classifiers, we compared the random forest classifier hazard ratio
(HR), the HR in the subset of patients with unanimous agreement across 24 preprocessing
pipelines, as well as the HR of individual preprocessing pipelines. Similarly, binary classifica-
tion measure accuracy was compared. To compare between the random forest classifiers
Ensembles of hypoxia signatures
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derived for each hypoxia signature, we assessed prognostic performance using the AUC. The
ROC analysis was conducted for each signature using the random forest classification proba-
bility (pROC v1.8).
Statistical comparison analysis
We compared the HR performance in the array of random forest classifier models for each
hypoxia signature. The classifier HRs were split based on the features used to build the classi-
fier: preprocessing pipelines, engineered variables, and feature variable selection. A paired t-
test was used to assess statistical differences in the log2-transformed Hazard Ratios.
New signature creation using preprocessing ensembles
Using the HG-U133A platform datasets, we sought to elucidate the ability of preprocessing
ensemble classifiers to improve upon performance of novel signatures. To this end, we gener-
ated a 100-top-ranked-gene novel signature for individual preprocessing pipelines. This was
done for preprocessing pipelines where all HG-U133A datasets were preprocessed together,
yielding 12 individual signatures. To ascertain the signatures, each preprocessing normaliza-
tion method was used to median-dichotomize the patient cohort by low or high abundance for
each gene. The unadjusted Cox proportional hazard model was used to determine the univari-
ate performance of individual genes to prognostic outcome. Statistical significance was
assessed using the Wald test and p-values were false-discovery rate (FDR) adjusted to correct
for multiple-testing. The 100 top-ranked genes with adjusted p-values < 0.05 were selected to
constitute the signature. The individual signatures from the 12 preprocessing pipelines were
validated using random forest classifiers using 10-fold cross-validation, where the random for-
est classifiers were trained on a training set and internally validated on a separate test set. The
12 good versus poor prognosis classifications were subsequently combined in a meta-random
forest to evaluate its ability to predict prognosis compared to individual signature classifiers.
The random forest model parameters were tuned as described above. Classification accuracy
for each breast cancer subtype was calculated by subsetting to patients with known subtype
information before dividing the number of correctly classified patients by the total number of
patients with the subtype. The ensemble classification accuracy was calculated using all
patients in this comparison.
The method outlined to generate an ensemble classifier was also applied to a previously
published prostate cancer methylation preprocessing dataset to further test the generalizability
of this method.
Program usage
All statistical analyses and plotting were performed in R statistical environment (v3.2.1). The
following packages were used for statistical analyses: randomForest v4.6.10, Boruta v4.0.0, sur-
vival v2.38.0, and pROC v1.8. All plots were generated in R using custom scripts for lattice
(v0.2.31) and latticeExtra (v0.6.26).
Results
Study design: Ensembles of preprocessing pipelines
Our overall approach to evaluate non-linear preprocessing ensembles is outlined in Fig 1. Our
goal was to determine how multiple pre-processing methods might best be combined to
improve biomarkers predictive of patient prognosis. The datasets used were separated based
on the microarray platform–HG-U133A and HG-U133 Plus 2.0 –because of previously
Ensembles of hypoxia signatures
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reported differences in their noise characteristics [19]. The union of all HG-U133A datasets
contains 1,564 patients while that of the HG-U133 Plus 2.0 datasets contains 579. Each individ-
ual dataset was preprocessed using 24 pipeline variants, and then each hypoxia signature was
scored for each pre-processing variant. This resulted in 24 predictions for each combination of
patient and signature. Additionally, we derived several engineered variables from counting the
total number of votes based on various preprocessing pipeline characteristics (S4 Table). Ran-
dom forest classifiers were constructed to predict prognosis for individual patients using com-
binations of the ensemble of 24 preprocessing pipeline predictions and the engineered
features. We evaluated the performance of these classifiers using Kaplan-Meier analysis, Cox
proportional hazard model, and the binary classification accuracy.
Different preprocessing ensembles perform best for different biomarkers
We compared the performance of the individual preprocessing pipelines with to those of
ensemble approaches. This process was conducted for each of the four hypoxia signatures and
both microarray platforms. S5 Table (HG-U133A) and S6 Table (HG-U133 Plus 2.0) comprise
the hazard ratios (HRs) and 95% confidence intervals (CIs) determined for each of the 24 pre-
processing pipelines, the random forest classifiers evaluated, and the simple preprocessing
unanimous classifier, for each signature. Note that in this design each classifier is evaluated on
a fully-independent validation cohort, to mitigate over-fitting.
Fig 2A shows a representative forest plot of the prognostic ability of various classifiers mea-
sured in HRs for the Winter metagene signature, using the HG-133A microarray platform.
The best prediction of prognosis was observed in the subset of patients with unanimous agree-
ment across the pipelines [HR 3.48, 95% confidence interval (CI) 2.44–4.95, p = 4.99 x 10−12].
However, the unanimous classification method only makes predictions for 41% (642) of
patients while the remainder are unclassified. With incorporation of all patients in the
HG-U133A dataset, the random forest classifier using engineered variables derived from votes
of preprocessing pipeline features appeared to be a better predictor of prognosis than any
Fig 1. Summary of the study design for ensemble classification for evaluation of a biomarker. Microarray data are obtained from specific platforms and
preprocessing using 24 different pipelines to normalize the mRNA gene expression. Risk groups are then assigned based on the biomarker of interest, resulting in a
collection of either good or poor prognosis stratification based on the expression obtained from various preprocessing methods. Stratification into either good or poor
prognosis represents a vote for that group, resulting in a score between 0 and 24. The ensemble of classifications is combined as features for random forest based
machine learning. Random forest classifiers learning on a selected training set and evaluated on the test set. The robustness of the classifier derived for the biomarker of
interest is evaluated with Cox proportional hazard ratio modeling and Kaplan-Meier survival estimates.
https://doi.org/10.1371/journal.pone.0204123.g001
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individual pipelines (HR 2.39, 95% CI 1.94–2.93, p = 9.89 x 10−17). Similarly, the prognostic
ability of two other ensemble random forest classifiers (preprocessing pipeline in combination
with engineered variables, and preprocessing pipelines ensemble) also performed better than
any individual pipelines (HR 2.25, 95% CI 1.83–2.76, p = 9.59 x 10−15 and HR 2.24, 95% CI
1.82–2.75, p = 1.41 x 10−14).
Surprisingly, though, this improved performance of random forest classifier of pre-process-
ing methods was not a general feature of signatures. Rather, the performance of the ensemble
classifier in comparison to individual pipeline variants was highly variable for the Buffa (S1
Fig) Hu (S2 Fig) and Sorensen signatures (S3 Fig). Further, the combination of features result-
ing in the best classifier was not consistent across the four signatures: engineered variables
were important for the Buffa and Winter signatures (Buffa: HR 2.15, 95% CI 1.75–2.64,
p = 4.03 x 10−13; Winter: HR 2.39, 95% CI 1.94–2.93, p = 9.89x 10−17), but feature selection
using the Boruta algorithm yielded the highest performing classifier for Hu (HR 1.63, 95% CI
1.32–2.00, p = 3.87 x 10−6) and Sorensen signatures (HR 2.28, 95% CI 1.87–2.78, p = 2.51 x
10−16).
These findings of strong divergence in the best way to merge pre-processing algorithms
held when we considered other metrics of classification accuracy besides HRs. For example,
classification accuracy and evaluation of the area under the receiver operating characteristics
curve (AUC) again show the benefits of specific pre-processing ensembles for the Winter
Fig 2. Representative hazard ratio forest plot and accuracy for Winter metagene signature using the HG-U133A microarray platform. (A) Forest plot of log2
hazard ratios with 95% confidence intervals obtained for each of the 24 preprocessing (PP) methods, the random forest classifiers evaluated, and the simple unanimous
vote classifier (total number of votes for poor prognosis either 0 or 24). The forest plot is ordered as decreasing hazard ratio. The dotted line represents a hazard ratio of
1. The blue hazard ratio with its 95% confidence interval represents the hazard ratio for the simple unanimous vote classifier. (B) Bar plot of accuracy obtained for each
of the 24 preprocessing methods, the random forest classifiers evaluated, and the simple unanimous vote classifier. The bars are ordered by preprocessing pipelines, the
unanimous classifier, and the best performing random forest classifier, from left to right.
https://doi.org/10.1371/journal.pone.0204123.g002
Ensembles of hypoxia signatures
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signature (Fig 2B) matching those in the HR analysis, and analogously for the Buffa (S1 Fig),
Hu (S2 Fig), and Sorensen signatures (S3 Fig).
These trends were also independent of the specific microarray platform used: results were
comparable in patients analyzed using the HG-U133 Plus 2.0 microarray platform (S4–S7
Figs). The preprocessing unanimous classifier based on simple risk voting resulted in superior
prognostication compared to individual preprocessing variants for all signatures except for
Sorensen. Furthermore, the random forest classifiers evaluated did not improve upon unani-
mous classification, except for the Sorensen signature. The best performing random forest
classifier was also inconsistent and variable across the biomarkers evaluated. The Kaplan-
Meier plots for the HG-U133A dataset are shown in S8–S11 Figs. The Kaplan-Meier plots for
the HG-U133 Plus 2.0 dataset are shown in S12–S15 Figs.
Comparison of patient prognosis prediction between signature classifiers
Taken together, our results show that it is possible to improve upon individual pre-processing
pipelines using ensemble techniques, but that the best way to assemble these ensembles varies
with the biomarker signature, and not the microarray platform. Fig 3A compares the best
ensemble of pre-processing methods to the best individual preprocessing method for each sig-
nature and microarray platform. Consistent with our previous results, the random forest clas-
sifier outperformed the preprocessing method for Winter and Sorensen signatures, but not for
Buffa and Hu signatures. The ROC curve and corresponding AUC obtained for the best
ensemble of preprocessing strategies is shown in Fig 3B and Fig 3C. The Buffa, Winter, and
Sorensen signature classifiers demonstrated similar AUCs for mortality risk stratification
between the two microarray platforms. Conversely, the Hu signature classifier showed better
risk stratification using the HG-U133 Plus 2.0 platform compared to the HG-U133A platform.
To determine if there are general properties of an ensemble of preprocessing methods that
contribute to its performance, we compared each classifier feature to the ultimate performance
of the classifier. This was done separately for both microarray platforms. For the HG-U133A
platform, patients where all preprocessing methods gave a consistent results (unanimous
preprocessing agreement) were statistically easier to classify than those where there was diver-
gence amongst the pre-processing methods. These patients are thus more difficult to prognose,
even though ensembles do improve upon the best individual pre-processing method. Similarly
for the HG-U133 Plus 2.0 platform, patients with unanimous preprocessing agreement were
statistically significantly or trend significantly easier to classify than those with divergence
across classifiers. This trend was consistent across all four signatures evaluated, and across
both platforms, suggesting that there is a patient sub-group that is fundamentally easier to
classify, and that on the agreement of pre-processing methods on this sub-group can give
increased confidence to the accuracy of molecular biomarkers.
Generalization to non-hypoxia signatures
To assess the generality of these observations, we trained independent prognostic signatures
on each pre-processing method (Fig 4). Thus the same training dataset was pre-processed in
12 distinct ways, and then a learner was applied to each of these, leading to 12 distinct prog-
nostic biomarkers. We focused on the HG-U133A data for this experiment, given its larger
sample-size. We selected a standard straight-forward machine-learning approach, involving
feature-selection with a univariate statistical text (Cox proportional hazards modeling) and
modeling using the non-metric random forest approach. We then evaluated whether these 12
separate classifiers gave similar predictions for each individual patient, and attempted to create
an ensemble of them. Finally the twelve separate and one ensemble classifiers were validated
Ensembles of hypoxia signatures
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on the independent validation dataset using the AUC and Cox proportional hazards
modeling.
The signatures trained with each of the 12 preprocessing pipelines had remarkably similar
accuracy and HRs (Fig 5A), and a subset of genes overlapped across multiple signatures (S7
Table). An ensemble of these 12 classifiers resulted in marginally, but not statistically signifi-
cant, improved predictions, suggesting that the signatures are not providing complementary
information. To verify this, we compared the agreement of the per-patient predictions across
all signatures. Fig 5B illustrates the predictions of individual signature classifiers across all
patients stratified by the true survival outcome. The signature showed highly concordant clas-
sification, with patients with mortality events were similarly classified as having poor prognosis
across the signatures and patients with continued survival were similarly classified as having
good prognosis across the signatures. Similarly, inaccurate predictions of survival and mortal-
ity occurred in a comparable subset of patients across the signatures. To determine if the
Fig 3. Summary hazard ratio forest plot and receiver operator curves. (A) Forest plot of log2 hazard ratios with 95% confidence intervals obtained for the best
performing preprocessing method, best performing random forest classifier, and the unanimous vote classifier. Plot is ordered by decreasing hazard ratio within each
signature and microarray platform evaluated. Colors correspond to the specific signature evaluated. (B and C) Receiver operator curves and area under the curve (AUC)
obtained from the best performing random forest classifier for each biomarker, as determined by the highest hazard ratio. HG-U133A ROC curves shown in A, and
HG-U133 Plus 2.0 ROC curves shown in B.
https://doi.org/10.1371/journal.pone.0204123.g003
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Fig 4. Summary of the study design for development of novel signature classifiers for each preprocessing pipeline and evaluating its performance in a meta-
ensemble classifier. Microarray data are obtained from specific platforms and preprocessing using 24 different pipelines to normalize the mRNA gene expression. The
gene expression is median dichotomized into two expression groups. Novel signatures are determined as the top 100 genes that reached significant after adjustment for
false discovery rate, for each preprocessing pipeline (total 12). The training of a random forest classifier based on the individual novel signatures result in individual risk
classifications of survival prognosis. These risk stratification are subsequently combined in a meta-random forest classifier to evaluate the robustness of the signature
with Cox proportional hazard ratio modeling and Kaplan-Meier survival estimates.
https://doi.org/10.1371/journal.pone.0204123.g004
Fig 5. Hazard ratio forest plots of classifier performance and heatmap of individual classifier predictions of survival prognosis. (A) Forest plot with 95%
confidence intervals of novel signature classifiers. The forest plot is ordered as decreasing hazard ratio. The dotted line represents a hazard ratio of 1. (B) Heatmap
of classifier predictions of 5-year survival status. The classifiers (by row) from signatures are ordered by decreasing performance of patient outcome prediction.
Patients (by column) are ordered by the degree of agreement of predictions across the array of novel signatures identified from 12 different preprocessing variant
pipelines. The true outcome of patients is shown as either 5-year survival status or overall survival status up to the end of study follow-up. Blue represents true
positives with correct prediction of poor prognosis. Purple represents true negatives with correct prediction of good prognosis. The white part of the heatmap
represents incorrect predictions of good or poor prognosis. (C) Classification accuracy of ensemble model stratified by known subtype of the tumours and of the
model itself when subsetted to samples with subtype information in the literature.
https://doi.org/10.1371/journal.pone.0204123.g005
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signature’s accuracy differed between subtypes, we subsetted the patients with known subtype
information from the literature and calculated classification accuracy (Fig 5C). We find that
accuracy was highest for normal-like and lowest for Luminal B, and these values can be further
improved during the model training process.
To further evaluate the generalizability of this ensemble method, we executed the workflow
on a prostate cancer methylation preprocessing dataset [33]. This set consists of the raw meth-
ylation values along with data from 11 preprocessing methods. Following the method previ-
ously outlined (Fig 4), individual classifiers were trained before training the ensemble
classifier. Similar to the results from the breast cancer data (Fig 5), the results from the prostate
cancer dataset showed that the ensemble classifier outperformed the majority of individual
classifiers at predicting biochemical recurrence (S16 Fig), but not all.
Taken together, it appears that all signatures predict either good or poor survival for a simi-
lar cohort of patients, and that there remains a group of patients whose prognosis is difficult to
predict and that leveraging orthogonal information from multiple pre-processing schemes will
not help in making more accurate predictions for these.
Discussion
Some groups have suggested that different preprocessing methods have minor effect on pre-
dictive signatures [42, 43]. Other work has suggested that this is incorrect, and that different
preprocessing algorithms results in substantial differences in outcomes [18, 19]. Indeed we
previously showed that ensemble classification combining preprocessing techniques using a
unanimous voting method could identify high-confidence predictions, thereby giving
increased confidence to risk stratification tools. We sought here to extend this approach and to
discover if the predictions from multiple pre-processing algorithms might be combined into
more accurate ensemble calls.
Our results demonstrate that there is indeed value to leveraging multiple pre-processing
techniques. However, they yield the surprising result that the optimal way to do so is depen-
dent on the characteristics of an individual signature. That is, one must consider all pre-pro-
cessing methodologies for each new biomarker to determine if and to what extent combining
them will improve predictions: there is no apparent universal approach to optimize this prob-
lem, even holding the dataset constant. Further, ensembles appear to be limited in the extent
to which they can improve signatures–there remains a subset of hard-to-classify patients for
whom varying characteristics of the pre-processing do not help in classification. Large inter-
individual differences exist in a plethora of extrinsic factors that play an equally imperative
role in driving survival outcomes. These include environmental exposure factors, socioeco-
nomic factors, patient compliance concerns, patient preferences, and social habits [44]. Treat-
ment factors include success of surgery such as extent of margins, factors involved in the
delivery of adjuvant treatments, as well as variability in the decision-making process between
the patient and the treating physician. Currently, much of this information is not considered
in the evaluation of intrinsic biological pattern on prognosis. Optimal prediction of outcomes
will likely necessitate the integration of both intrinsic and extrinsic information in the bio-
marker development process. These findings are thus highly consistent with that demonstrated
by Tofigh et al., whereby the prognosis for a subset of breast cancer patients was intrinsically
more difficult to predict [45].
Our results are not without limitations. First, the datasets included in the analyses herein
represent only therapy-naïve early breast cancer tumors. It is well known that cancer is a dis-
ease of many, given the inter-tumor and intra-tumor heterogeneity observed. This precludes
generalizations of these results to other tumor types. Second, we used random forests to derive
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classifiers, but potentially other machine learning algorithms may yield different results.
Third, our study focused on four previously published hypoxia signatures and it would be dif-
ficult to extrapolate our findings to other microarray-based signatures. Studies are needed to
elucidate the findings herein for other clinically promising signatures. Lastly, we only used
microarray datasets to assess the utility of random forest classifiers for risk stratification. It
may be that preprocessing ensemble classifications will be of greater benefit in fields where
existing preprocessing methods are less robust [46].
Taken together, our data further highlights the need to incorporate extrinsic factors not
accounted for by intrinsic biological signals, in the pursuit of integrative signatures that will
allow for the realization of precision oncology.
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